The long-delayed and much-speculated-about data from Merck and Schering-Plough’s Enhance study comparing whether a combination of Zetia and Zocor works better than Zocor alone were finally released today. Bottom line: Zetia, or ezetimibe generically, didn’t bring anything important to the cholesterol party. The telling detail: there was no statistically significant difference in the primary endpoint of the study, a marker of atherosclerotic changes in the arteries called intima-media thickness, according to a Schering-Plough press release. The results of this two-year-long trial of 720 people with heterozygous familial hypercholesterolemia (HeFH), a rare, inherited form of high cholesterol that affects about 0.2% of the population, have been eagerly anticipated. The study was finished in 2006, and the findings were expected to be disclosed finally in March at a meeting of heart doctors. |
No comments:
Post a Comment